mouse normal hepatocyte cell line aml12  (ATCC)

Journal: Science Advances

Article Title: SLC13A2-transported citrate remodels transcriptional regulation through protein acetylation to suppress tumor growth

doi: 10.1126/sciadv.aec4368

Figure Lengend Snippet: ( A ) Liver tumor tissues were collected from the HTVi model and clinical patients and subjected to untargeted metabolomic profiling for pathway enrichment. ( B ) Summarized SLC transporters for TCA cycle intermediates. ( C ) Forest plot showing the hazard ratios (HR) for multiple genes encoding SLC transporters of TCA cycle intermediates in HCC. The horizontal line represents the 95% confidence interval. ( D ) Heatmap of detectable SLC transporters for TCA cycle intermediates in heterogeneous primary liver cancer models generated by genome editing of cancer driver genes selected by mutational frequency from human HCC cohorts (PRJNA674008). ( E ) qPCR analysis to screen candidate SLC transporters for HCC progression based on the relative expression of SLC transporters in the HTVi model ( n = 4 for the control group and n = 5 for the model group), mouse HCC Hepa1-6 cells, AML12 cells, and MPHs ( n = 3 independent experiments). ( F ) Venn diagram showing the overlap of significantly differentially expressed SLC transporters in the HTVi model, mouse HCC Hepa1-6 cells, and normal hepatocytes (AML12 and MPHs). ( G and H ) SLC13A2 expression in liver tissues from HTVi, AAV-cMYC/nRAS, and STZ-HFD HCC model. The data are presented as means ± SEM. * P < 0.05; ** P < 0.01, two-tailed unpaired Student’s t test. Ctrl, control; n.d., not determined; NS, not significant.

Article Snippet: The mouse HCC cell line Hepa1-6 and mouse normal hepatocyte cell line AML12 were obtained from the American Type Culture Collection as described previously ( ).

Techniques: Metabolomic, Generated, Expressing, Control, Two Tailed Test

Journal: Discover Oncology

Article Title: Isosilybin B: a potential novel therapeutic agent with hepatoprotective, anticancer and antifibrotic properties

doi: 10.1007/s12672-025-03380-8

Figure Lengend Snippet: Effect of IB/SB/SM on cytotoxicity and cell cycle arrest of liver cells. A : Chemical structure of IB and SB (silybin A and silybin B in ratio 1:1). Cytotoxicity in Hepa1-6 ( B ), HepG2 ( C ) or AML12 ( D ) liver cells after 24 h treatment with IB/SB/SM. Changes in the cell cycle in Hepa1-6 ( E ), HepG2 ( F ), or AML12 ( G ) liver cells after 24 h treatment with 31.3 µg/mL of IB/SB/SM. H : Cell distribution of diploid cells in the phases of the cell cycle shown for IB (31.3 µg/mL). The data are given as means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: Mouse normal liver hepatocyte cell line AML12 (RRID: CVCL_0140, ATCC, USA) was cultivated in DMEM/F12 medium supplemented with 10% FBS, 1% penicillin-streptomycin, 1X Insulin-Transferrin-Selenium and 40 ng/mL dexamethasone.

Techniques:

Journal: Discover Oncology

Article Title: Isosilybin B: a potential novel therapeutic agent with hepatoprotective, anticancer and antifibrotic properties

doi: 10.1007/s12672-025-03380-8

Figure Lengend Snippet: Effect of IB/SB/SM on pro-fibrotic gene expression, antioxidant activity, and ALT concentration in AML12 cells. (A-C) Expression of pro-fibrotic genes fibronectin ( Fn1 ), smooth muscle actin ( Acta2 ) and collagen I ( Col1a1 ) after 24 h treatment with TGF-β1 (10 ng/mL) and IB/SB/SM (7.8–31.3 µg/mL) in AML12 cells. (D) Western blot analysis of fibronectin expression in AML12 cells stimulated for 24 h with TGF-β1 (10 ng/mL) and IB/SB/SM at concentration 31.3 µg/mL. Representative western blot bands are shown below the graphs. (E) DPPH antioxidant activity assay. The ability of IB/SB/SM to scavenge DPPH radicals was evaluated at various concentrations (0–500 µg/mL). (F) Determination of alanine aminotransferase (ALT) concentration in the supernatants of AML 12 cells stimulated with TGF-β1 (10 ng/mL) in the presence of the tested compounds (IB, SB, SM) at different concentrations. All results are expressed as mean ± SD, * p < 0.05, ** p < 0.01, *** p < 0,001 (for western blot: vs. TGF-β1 control)

Article Snippet: Mouse normal liver hepatocyte cell line AML12 (RRID: CVCL_0140, ATCC, USA) was cultivated in DMEM/F12 medium supplemented with 10% FBS, 1% penicillin-streptomycin, 1X Insulin-Transferrin-Selenium and 40 ng/mL dexamethasone.

Techniques: Gene Expression, Antioxidant Activity Assay, Concentration Assay, Expressing, Western Blot, Control

Journal: International Journal of Nanomedicine

Article Title: Liver-Targeting Nanoparticles GA-MSe@AR Treat NAFLD Through Dual Lipid-Lowering and Antioxidant Efficacy

doi: 10.2147/IJN.S510577

Figure Lengend Snippet: GA-MSe@AR reduced body weight and blood biochemical parameters in mice. ( A ) Scheme of the mouse experiment. C57BL/6J mice were randomly divided into five groups (n = 6). The mice received either a low-fat diet (LFD, 10% kcal fat) with saline, or a high-fat diet (HFD, 60% kcal fat) supplemented with saline, GA-MSe, AR, or GA-MSe@AR (all at 5 mg/kg, administered twice weekly, i.v.) for 16 weeks. ( B ) Body weight changes of mice in each group during the experiment. Blood glucose ( C ), serum total cholesterol (TC) ( D ), and serum triglycerides (TG) ( E ) were measured to evaluate the metabolic status of the mice. Liver injury markers alanine aminotransferase (ALT) ( F ) and aspartate aminotransferase (AST) ( G ) were measured to assess the extent of hepatocyte injury in each group of mice. * p <0.05, ** p <0.01, *** p <0.001.

Article Snippet: The human and mouse normal hepatocyte cell line (LO2 cells and AML12 cells) were purchased from American Type Culture Collection (ATCC, Manassas, USA).

Techniques: Saline